Skip to main content
D

Diamond Biofund Inc. — Investor Relations & Filings

Ticker · 6901 TW Financial and insurance activities
Open in API
Filings indexed 19 across all filing types
Latest filing 2026-04-09 Regulatory Filings
Country TW Taiwan
Listing TW 6901

About Diamond Biofund Inc.

http://www.diamondbiofund.com

Diamond Biofund Inc. is a professional venture capital firm dedicated to the life sciences and healthcare sectors. Established through a partnership between the Microbio Group and prominent financial institutions, the company operates as a large-scale evergreen fund focused on long-term industrial development. Its core strategy involves identifying and nurturing high-potential startups from the laboratory stage to market commercialization. The firm specializes in high-risk areas such as innovative drug discovery, advanced medical devices, and agricultural biotechnology. Beyond capital injection, Diamond Biofund provides strategic value-added services, including intellectual property management, clinical validation, and operational guidance. By integrating expertise in research, finance, and corporate management, the firm aims to build flagship enterprises and reduce the inherent risks of early-stage innovation.

Recent filings

Filing Released Lang Actions
115年3月背書保證與資金貸與
Regulatory Filings Classification · 1% confidence The document is a mandatory disclosure of fund lending and endorsement guarantee balances (“資金貸放餘額” and “背書保證資訊”) by a Taiwanese listed company for March, showing zero balances across company and subsidiaries. It is not an earnings announcement, board change, dividend notice, investor presentation, or any specific financial report type. Instead, it is a typical regulatory disclosure under Taiwan’s public information system, falling under the general Regulatory Filings category.
2026-04-09 Chinese
115年3月營業收入
Regulatory Filings Classification · 1% confidence The document is a monthly revenue summary table (“查詢彙總報表”) extracted from the Taiwan Market Observation Post System (MOPS), showing net operating income for a specific month and year-to-date with explanatory footnotes. It is a regulatory disclosure of periodic financial data rather than a full annual/interim report, earnings release, or investor presentation, and the data is provided directly rather than as an announcement of a separately attached document. It does not fit any highly specific category, so it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-09 Chinese
115年03月內部人持股異動(事後)
Director's Dealing Classification · 1% confidence The document is a detailed table disclosing insider share holdings and any share movements by directors, executives, and major shareholders. It lists each insider’s share counts at month-end and any increases/decreases, fitting the definition of a personal share transactions disclosure. This corresponds to “Director’s Dealing” (Code: DIRS).
2026-04-07 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 1% confidence The document is a disclosure of company insiders’ shareholdings (directors, supervisors, senior management) and pledge status, detailing “選任時持股” vs “目前持股” etc. This is a mandated insider share disclosure rather than a full financial report or earnings release. It falls under Director’s Dealing (insider shareholding disclosure).
2026-04-07 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.